|
1 | | -figshare: "https://api.figshare.com/v2/articles/26409316" |
2 | | -version: "0.1.4" |
| 1 | +figshare: "https://api.figshare.com/v2/articles/28250603" |
| 2 | +version: "2.0.0" |
3 | 3 | datasets: |
4 | 4 | beataml: |
5 | 5 | description: "Beat acute myeloid leukemia (BeatAML) focuses on acute myeloid leukemia tumor data. Data includes drug response, proteomics, and transcriptomics datasets." |
6 | | - doi: "https://doi.org/10.1016/j.ccell.2022.07.002" |
| 6 | + references: |
| 7 | + - citation: "Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850-864.e9." |
| 8 | + doi: "https://doi.org/10.1016/j.ccell.2022.07.002" |
| 9 | + - citation: "Pino JC, Posso C, Joshi SK, et al. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia. Cell Rep Med. 2024;5(1):101359." |
| 10 | + doi: "https://doi.org/10.1016/j.xcrm.2023.101359" |
| 11 | + ccle: |
| 12 | + description: "Cancer Cell Line Encyclopedia (CCLE)." |
| 13 | + references: |
| 14 | + - citation: "Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature. 2012;483(7391):603-607. Published 2012 Mar 28." |
| 15 | + doi: "https://doi.org/10.1038/nature11003" |
7 | 16 | cptac: |
8 | 17 | description: "The Clinical Proteomic Tumor Analysis Consortium (CPTAC) project is a collaborative network funded by the National Cancer Institute (NCI) focused on improving our understanding of cancer biology through the integration of transcriptomic, proteomic, and genomic data." |
| 18 | + references: |
| 19 | + - citation: "Lindgren CM, Adams DW, Kimball B, et al. Simplified and Unified Access to Cancer Proteogenomic Data. J Proteome Res. 2021;20(4):1902-1910." |
| 20 | + doi: "doi:10.1021/acs.jproteome.0c00919" |
| 21 | + ctrpv2: |
| 22 | + description: "Cancer Therapeutics Response Portal version 2 (CTRPv2)" |
| 23 | + references: |
| 24 | + - citation: "Rees MG, Seashore-Ludlow B, Cheah JH, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109-116." |
| 25 | + doi: "doi:10.1038/nchembio.1986" |
| 26 | + - citation: "Seashore-Ludlow B, Rees MG, Cheah JH, et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov. 2015;5(11):1210-1223." |
| 27 | + doi: "doi:10.1158/2159-8290.CD-15-0235" |
| 28 | + - citation: "Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154(5):1151-1161." |
| 29 | + doi: "doi:10.1016/j.cell.2013.08.003" |
| 30 | + fimm: |
| 31 | + description: "Institute for Molecular Medicine Finland (FIMM) dataset." |
| 32 | + references: |
| 33 | + - citation: "Mpindi JP, Yadav B, Östling P, et al. Consistency in drug response profiling. Nature. 2016;540(7631):E5-E6." |
| 34 | + doi: "doi:10.1038/nature20171" |
| 35 | + - citation: "Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3(12):1416-1429." |
| 36 | + doi: "doi:10.1158/2159-8290.CD-13-0350" |
| 37 | + gcsi: |
| 38 | + description: "The Genentech Cell Line Screening Initiative (gCSI)" |
| 39 | + references: |
| 40 | + - citation: "Haverty PM, Lin E, Tan J, et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature. 2016;533(7603):333-337." |
| 41 | + doi: "https://doi.org/10.1038/nature17987" |
| 42 | + - citation: "Klijn C, Durinck S, Stawiski EW, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33(3):306-312." |
| 43 | + doi: "https://doi.org/10.1038/nbt.3080" |
| 44 | + gdscv1: |
| 45 | + description: "Genomics of Drug Sensitivity in Cancer (GDSC) v1" |
| 46 | + references: |
| 47 | + - citation: "Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570-575. Published 2012 Mar 28." |
| 48 | + doi: "doi:10.1038/nature11005" |
| 49 | + - citation: "Iorio F, Knijnenburg TA, Vis DJ, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016;166(3):740-754." |
| 50 | + doi: "doi:10.1016/j.cell.2016.06.017" |
| 51 | + - citation: "Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955-D961." |
| 52 | + doi: "doi:10.1093/nar/gks1111" |
| 53 | + gdscv2: |
| 54 | + description: "Genomics of Drug Sensitivity in Cancer (GDSC) v2" |
| 55 | + references: |
| 56 | + - citation: "Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570-575. Published 2012 Mar 28." |
| 57 | + doi: "doi:10.1038/nature11005" |
| 58 | + - citation: "Iorio F, Knijnenburg TA, Vis DJ, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016;166(3):740-754." |
| 59 | + doi: "doi:10.1016/j.cell.2016.06.017" |
| 60 | + - citation: "Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955-D961." |
| 61 | + doi: "doi:10.1093/nar/gks1111" |
9 | 62 | hcmi: |
10 | 63 | description: "Human Cancer Models Initiative (HCMI) encompasses numerous cancer types and includes cell line, organoid, and tumor data. Data includes the transcriptomics, somatic mutation, and copy number datasets." |
11 | 64 | mpnst: |
12 | 65 | description: "Malignant Peripheral Nerve Sheath Tumor is a rare, agressive sarcoma that affects peripheral nerves throughout the body." |
| 66 | + references: |
| 67 | + - citation: "Dehner C, Moon CI, Zhang X, et al. Chromosome 8 gain is associated with high-grade transformation in MPNST. JCI Insight. 2021;6(6):e146351. Published 2021 Mar 22." |
| 68 | + doi: "https://doi.org/10.1172/jci.insight.146351" |
| 69 | + mpnstpdx: |
| 70 | + description: "Patient derived xenograft data for MPNST" |
| 71 | + nci60: |
| 72 | + description: "National Cancer Institute 60" |
| 73 | + references: |
| 74 | + - citation: "Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813-823." |
| 75 | + doi: "doi:10.1038/nrc1951" |
| 76 | + prism: |
| 77 | + description: "Profiling Relative Inhibition Simultaneously in Mixtures" |
| 78 | + references: |
| 79 | + - citation: "Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1(2):235-248." |
| 80 | + doi: "doi:10.1038/s43018-019-0018-6" |
| 81 | + - citation: "Yu C, Mannan AM, Yvone GM, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016;34(4):419-423." |
| 82 | + doi: "doi:10.1038/nbt.3460" |
0 commit comments